Association of immune recovery with hyperlipidaemia and apolipoprotein gene polymorphisms following highly active antiretroviral therapy in a cohort of Chinese HIV patients

被引:3
|
作者
Chan, Denise Pui-Chung [1 ]
Lee, Man-Po [2 ]
Wong, Ngai-Sze [1 ]
Leung, Ross Ka-Kit [1 ]
Naftalin, Claire Melinda [1 ]
Lee, Shui-Shan [1 ]
机构
[1] Chinese Univ Hong Kong, Stanley Ho Ctr Emerging Infect Dis, Shatin, Hong Kong, Peoples R China
[2] Queen Elizabeth Hosp, Dept Med, Kowloon, Hong Kong, Peoples R China
来源
BMJ OPEN | 2016年 / 6卷 / 04期
关键词
SINGLE NUCLEOTIDE POLYMORPHISMS; INFECTED PATIENTS; DISEASE; INFLAMMATION; MARKERS; RISK; HYPERTRIGLYCERIDEMIA; DYSLIPIDEMIA; ACTIVATION; LIPIDS;
D O I
10.1136/bmjopen-2015-010998
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To examine the associations between CD4 recovery, dyslipidaemia and apolipoprotein (APO) gene single nucleotide polymorphisms (SNPs) following highly active antiretroviral therapy (HAART). Design: Retrospective observational cohort study. Setting: A major HIV care clinic in Hong Kong. Participants: 197 Chinese treatment-naive HIV patients. Outcome measures: Maximum CD4 count and its rise 2-3 years after HAART initiation and their association with abnormal total cholesterol (TC), triglyceride (TG) and 8 selected APO SNP at multiple time points. Results: Before HAART, abnormal levels of TC, TG, high-density lipoprotein cholesterol and low-density lipoprotein cholesterol were detected in 13%, 26%, 59% and 19% of the recruited patients, respectively. APOA5 - 1131T>C and c.553G>T were significantly associated with high pre-HAART TG while APOE 2198C>T was correlated with high TG at baseline and/or a rise 2-3 years following HAART initiation. Poor CD4 achievement, defined as the highest CD4 count <350/mu L and a net gain of <100/mu L, was associated with a low CD4 count <= 200/mu L at baseline and a rise of TC beyond 5.17 mmol/L following HAART with or without the use of antilipid agents. Conversely, satisfactory CD4 achievement was associated with APOC3 3238GG genotype. Applying a linear generalised estimating equation, APOA5 -1131T>C was shown to be a predictor of a weaker temporal trend for CD4 response in the presence of a low baseline CD4 <= 200/mu L. Conclusions: Dyslipidaemia plays a predictive role in impacting immunological recovery following HAART, which could be partly explained by the APO gene SNP.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Short Communication: Apoptosis Pathways in HIV-1-Infected Patients Before and After Highly Active Antiretroviral Therapy: Relevance to Immune Recovery
    Pitrak, David L.
    Novak, Richard M.
    Estes, Randee
    Tschampa, Jean
    Abaya, Christina D.
    Martinson, Jeffrey
    Bradley, Kirsten
    Tenorio, Allan R.
    Landay, Alan L.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2015, 31 (02) : 208 - 216
  • [42] Thymic Function during 12 Months of Highly Active Antiretroviral Therapy in Thai HIV-Infected Patients with Normal and Slow Immune Recovery
    Kingkeow, Doungnapa
    Srithep, Sarinee
    Praparattanapan, Jutarat
    Supparatpinyo, Khuanchai
    Pornprasert, Sakorn
    JAPANESE JOURNAL OF INFECTIOUS DISEASES, 2015, 68 (05) : 353 - 356
  • [43] Lower incidence and severity of cytomegalovirus-associated immune recovery uveitis in HIV-infected patients with delayed highly active antiretroviral therapy
    Ortega-Larrocea, G
    Espinosa, E
    Reyes-Terán, G
    AIDS, 2005, 19 (07) : 735 - 738
  • [44] CMV retinitis and the controversies associated with highly active antiretroviral therapy and the immune recovery hypothesis
    Reed, JB
    Morse, LS
    AIDS PATIENT CARE AND STDS, 1998, 12 (03) : 181 - 185
  • [45] Contraception choices in a cohort of HIV plus women in the era of highly active antiretroviral therapy
    Ezeanolue, Echezona E.
    Stumpf, Paul G.
    Soliman, Evelen
    Fernandez, George
    Jack, Ineada
    CONTRACEPTION, 2011, 84 (01) : 94 - 97
  • [46] Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-Naive HIV-Infected individuals
    Antonucci, G
    Girardi, E
    Cozzi-Lepri, A
    Capobianchi, MR
    De Luca, A
    Puoti, M
    Petrelli, E
    Carnevale, G
    Rizzardini, G
    Grossi, PA
    Viganò, P
    Moioli, MC
    Carletti, F
    Solmone, M
    Ippolito, G
    Monforte, AD
    CLINICAL INFECTIOUS DISEASES, 2005, 40 (12) : E101 - E109
  • [47] EVOLUTION OF RENAL FUNCTION IN A LARGE COHORT OF HIV POSITIVE PATIENTS TREATED WITH HIGHLY ACTIVE ANTIRETROVIRAL THERAPY: A RETROSPECTIVE COHORT STUDY
    Lamine, Nesrine
    Garjau, Maria
    Delforge, Marc
    De Wit, Stephane
    Wissing, Karl M.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 : 41 - 41
  • [48] Reduction of Immune System Activation in HIV-1-Infected Patients Undergoing Highly Active Antiretroviral Therapy
    J. M. Franco
    A. Rubio
    C. Rey
    M. Leal
    J. Macías
    J. A. Pineda
    B. Sánchez
    A. Sánchez-Quijano
    A. Nuñez-Roldán
    E. Lissen
    European Journal of Clinical Microbiology and Infectious Diseases, 1999, 18 : 733 - 736
  • [49] The prevalence and risk of immune restoration disease in HIV-infected patients treated with highly active antiretroviral therapy
    Jevtovic, D
    Salemovic, D
    Ranin, J
    Pesic, I
    Zerjav, S
    Djurkovic-Djakovic, O
    HIV MEDICINE, 2005, 6 (02) : 140 - 143
  • [50] Evaluation of a 6-Year Highly Active Antiretroviral Therapy in Chinese HIV-1-Infected Patients
    Zhou, Hua-ying
    Zheng, Yu-huang
    He, Yan
    Chen, Zi
    Liu, Meng
    Yin, Wei
    Liu, Chun
    INTERVIROLOGY, 2010, 53 (04) : 240 - 246